



2022 AGM UPDATE

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'AROA' or the 'Company') advises that following recent incidences of COVID-19 amongst staff at our registered office (64 Richard Pearse Drive, Mangere, Auckland, New Zealand), the Company is electing to hold its upcoming 2022 Annual General Meeting ('AGM') as a virtual-only meeting. The AGM is scheduled for 1pm (NZT) / 11am (AEST) on Wednesday, 10 August 2022. We consider this to be in the best interests of the health & safety of our stakeholders. Register here to attend the virtual meeting https://us02web.zoom.us/webinar/register/WN_Akzo_HtXTyGov-u_UfQiMA. Further instructions for attending the virtual meeting remain as set out in the Notice of Meeting released to the ASX on 13 July 2022.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. AROA's products have been used in more than four and a half million procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). www.aroabio.com

Contacts

Investor

Simon Hinsley
Investor Relations
shinsley@aroabio.com
+ 61 401 809 653

Media

Australia

Matthew Wright
matt@nwrcommunications.com.au
+61 451 896 420

New Zealand

Piet De Jong
piet.dejong@baldwinboyle.com
+64 21 812 766